173 related articles for article (PubMed ID: 16464187)
1. Designing naturalistic prospective studies of economic and effectiveness outcomes associated with novel antipsychotic therapies.
Tunis SL; Johnstone BM; Kinon BJ; Barber BL; Browne RA
Value Health; 2000; 3(3):232-42. PubMed ID: 16464187
[TBL] [Abstract][Full Text] [Related]
2. Clinical trial-based cost-effectiveness analyses of antipsychotic use.
Polsky D; Doshi JA; Bauer MS; Glick HA
Am J Psychiatry; 2006 Dec; 163(12):2047-56. PubMed ID: 17151153
[TBL] [Abstract][Full Text] [Related]
3. Pharmacoeconomic evaluation of antipsychotic therapy for schizophrenia.
Glazer WM; Johnstone BM
J Clin Psychiatry; 1997; 58 Suppl 10():50-4. PubMed ID: 9265917
[TBL] [Abstract][Full Text] [Related]
4. Updating and confirming an industry-sponsored pharmacoeconomic model: comparing two antipsychotics in the treatment of schizophrenia.
Graham CN; Mauskopf JA; Lawson AH; Ascher-Svanum H; Bruhn D
Value Health; 2012 Jan; 15(1):55-64. PubMed ID: 22264972
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care.
Stargardt T; Weinbrenner S; Busse R; Juckel G; Gericke CA
J Ment Health Policy Econ; 2008 Jun; 11(2):89-97. PubMed ID: 18509216
[TBL] [Abstract][Full Text] [Related]
6. Pharmacoeconomic evaluation of schizophrenia in Taiwan: model comparison of long-acting risperidone versus olanzapine versus depot haloperidol based on estimated costs.
Yang YK; Tarn YH; Wang TY; Liu CY; Laio YC; Chou YH; Lee SM; Chen CC
Psychiatry Clin Neurosci; 2005 Aug; 59(4):385-94. PubMed ID: 16048443
[TBL] [Abstract][Full Text] [Related]
7. Pharmacoeconomics of antipsychotic drug therapy.
Hargreaves WA; Shumway M
J Clin Psychiatry; 1996; 57 Suppl 9():66-76. PubMed ID: 8823354
[TBL] [Abstract][Full Text] [Related]
8. What do large scale studies of medication in schizophrenia add to our management strategies?
Agius M; Davis A; Gilhooley M; Chapman S; Zaman R
Psychiatr Danub; 2010 Jun; 22(2):323-8. PubMed ID: 20562774
[TBL] [Abstract][Full Text] [Related]
9. [Economic analyses of olanzapine in the treatment of schizophrenia and bipolar disorder].
Dilla T; Prieto L; Ciudad A; Sacristán JA
Actas Esp Psiquiatr; 2004; 32(5):269-79. PubMed ID: 15529211
[TBL] [Abstract][Full Text] [Related]
10. The impact of atypical antipsychotic medications on the use of health care by patients with schizophrenia.
Chen L; McCombs JS; Park J
Value Health; 2008; 11(1):34-43. PubMed ID: 18237358
[TBL] [Abstract][Full Text] [Related]
11. Methods of cost-effectiveness analysis in the evaluation of new antipsychotics: implications for schizophrenia treatment.
Neumann PJ
J Clin Psychiatry; 1999; 60 Suppl 3():9-14; discussion 15. PubMed ID: 10073371
[TBL] [Abstract][Full Text] [Related]
12. Clinical and pharmacoeconomic evaluation of switch to olanzapine in veterans with schizophrenia or schizoaffective disorder.
Davis LL; Cates ME; Lowe JS; Ward LC; Johnson JD; Williford RB; Ambrose SM; Thomas BL; Kashner TM
Psychopharmacol Bull; 2008; 41(1):85-98. PubMed ID: 18362873
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia.
Rosenheck RA; Leslie DL; Sindelar J; Miller EA; Lin H; Stroup TS; McEvoy J; Davis SM; Keefe RS; Swartz M; Perkins DO; Hsiao JK; Lieberman J;
Am J Psychiatry; 2006 Dec; 163(12):2080-9. PubMed ID: 17151158
[TBL] [Abstract][Full Text] [Related]
14. Pharmacy cost evaluation of risperidone, olanzapine, and quetiapine for the treatment of schizophrenia in acute care inpatient settings.
Mladsi DM; Grogg AL; Irish WD; Lopez RB; Degen K; Swann A; Nimsch CT
Curr Med Res Opin; 2004 Dec; 20(12):1883-93. PubMed ID: 15701206
[TBL] [Abstract][Full Text] [Related]
15. Methods of pharmacoeconomic evaluation of psychopharmacologic therapies for patients with schizophrenia.
Revicki DA
J Psychiatry Neurosci; 1997 Jul; 22(4):256-66. PubMed ID: 9262048
[TBL] [Abstract][Full Text] [Related]
16. Cost effectiveness of the newer atypical antipsychotics: a review of the pharmacoeconomic research evidence.
Revicki DA
Curr Opin Investig Drugs; 2001 Jan; 2(1):110-7. PubMed ID: 11527002
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of olanzapine as a first-line treatment: a comment.
Basu A
Value Health; 2006; 9(5):357; author reply 358. PubMed ID: 16961554
[No Abstract] [Full Text] [Related]
18. Decision analysis model evaluating the cost-effectiveness of risperidone, olanzapine and haloperidol in the treatment of schizophrenia.
Bounthavong M; Okamoto MP
J Eval Clin Pract; 2007 Jun; 13(3):453-60. PubMed ID: 17518814
[TBL] [Abstract][Full Text] [Related]
19. Risperidone compared with olanzapine in a naturalistic clinical study: a cost analysis.
Taylor DM; Wright T; Libretto SE;
J Clin Psychiatry; 2003 May; 64(5):589-97. PubMed ID: 12755664
[TBL] [Abstract][Full Text] [Related]
20. An analysis of the effect of funding source in randomized clinical trials of second generation antipsychotics for the treatment of schizophrenia.
Montgomery JH; Byerly M; Carmody T; Li B; Miller DR; Varghese F; Holland R
Control Clin Trials; 2004 Dec; 25(6):598-612. PubMed ID: 15588746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
